Studies on tumor microenvironment (TME) in patients with Luminal HER2 negative BC are scarce, probably due to the high global survival rates (92.5% at 4 years) and the efficacy of the already existing therapies [28]. This evidence concerns the gene ERBB2 and breast cancer.